China’s psoriasis market has grown significantly over the last few years owing to the growing use of biologics to treat the disease. We expect the market to expand further over the 2021-2031 forecast period from $424 million to $942 million, fueled by the continued uptake of targeted therapies—i.e., IL-17 inhibitors, IL-12 / IL-23 inhibitors, IL-23 inhibitors, and TNF-α inhibitors—as well as the entry of novel oral systemic therapies, including Amgen / Fosun’s Otezla and BMS’s deucravacitinib. While the evolving market access and reimbursement framework (e.g., NRDL, VBP programs) in China will improve patients’ access to these treatments, use of most of these drugs will still be relegated to later lines of therapy owing to reimbursement restrictions as they penetrate a market comprising a large array of entrenched traditional treatment options including topicals and conventional oral systemics (e.g., MTX, acitretin), most of which are generically available.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with dermatologists. Supported by survey data collected for this and other Clarivate research.
Diagnosed prevalence of psoriasis in urban versus rural China; clinically relevant and market-relevant drug-treatable populations.
Ten-year, annualized, drug-level sales and patient shares of key psoriasis therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: 8+ agents; Phase II: 5+ agents.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.